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Studies focused on development of an attenuated vaccine against Mycobacterium
avium subsp. paratuberculosis (Map), the causative agent of paratuberculosis (Ptb)
in cattle and other species, revealed that deletion of relA, a global gene regulator,
abrogates the ability of Map to establish a persistent infection. In the absence of
relA, cattle develop CD8 cytotoxic T cells (CTL) with the ability to kill intracellular
bacteria. Analysis of the recall response to a relA mutant, Map/1relA, with cells
from a vaccinated steer demonstrated that a 35-kDa membrane peptide (MMP) is
one of the targets of the response. This observation suggested that it might be
possible to develop a peptide-based vaccine. As reported here, the gene encoding
the hypothetical MMP ORF, MAP2121c, was modified for expression in mammalian
cells as a first step in developing an expression cassette for incorporation into a
mammalian expression vector. The modified sequence of MMP, tPA-MMP, was mutated
to generate two additional sequences for the study, one with substitutions to replace
five potential residues that could be glycosylated, tPA-MMP-5mut, and one with
substitutions to replace the first two potential residues that could be glycosylated,
tPA-MMP-2mut. The sequences were placed in an expression cassette to produce
peptides for analysis. An ex vivo platform was used with flow cytometry and a
bacterium viability assay to determine if modifications in the gene encoding MMP
for expression in mammalian cells altered its capacity to elicit development of CD8
CTL, essential for its use in a peptide-based vaccine. Monocyte-depleted PBMC
(mdPBMC) were stimulated with antigen-presenting cells (APC) pulsed with different
MMP constructs. CD4 and CD8T cells proliferated in response to stimulation with MMP
(control) expressed in Escherichia coli (eMMP), tPA-MMP, and tPA-MMP-2mut. CD8T
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cells retained the capacity to kill intracellular bacteria. The tPA-MMP-5mut failed to elicit
a proliferative response and was not included in further studies. The data show that the
expression cassettes containing MMP and MMP-2mut can be used to screen and select
a mammalian expression vector for the development of an efficacious peptide-based
vaccine against Ptb.
Keywords: Ptb, MMP, mammalian expression vector, immune response, vaccine
INTRODUCTION
Mycobacterium avium subsp. paratuberculosis (Map) is a
mycobacterial pathogen with a broad host range that includes
livestock, humans, and wildlife (1–5). It is the causative agent of
paratuberculosis (Ptb) in livestock. Ptb (also referred to as Johne’s
disease) has become a major disease problem in dairy ruminants,
especially in cattle. Similar to other pathogenic mycobacteria,
initial infection leads to development of a persistent infection
under immune control. For yet unknown reasons, this protective
immunity is dysregulated two or more years post-infection,
allowing for development of clinical disease. The inability to
detect infected animals during the early (latent) stages of
infection has led to the inadvertent spread of Ptb via introduction
of latently infected animals into clean herds worldwide. Attempts
to clear Map from livestock herds using management strategies
and improved early diagnostic methods has not been successful
(6–10). Thus, development of a Map livestock vaccine is
urgently needed.
Past efforts with killed vaccines revealed that vaccination
reduces the incidence of clinical disease, but does not prevent
establishment of infection and fecal shedding (11, 12). Similar
results have been reported with peptide-based vaccines (13,
14). Subsequently, attenuated Map strains were developed as
potential live vaccines, and efforts to discover potential peptide
vaccine targets continue (13, 15, 16). A major limitation of
previous and ongoing endeavors has been the lack of methods
to fully evaluate the immune response to candidate live and
peptide-based vaccines. As a consequence, there has been a
lingering question as to whether there is an age-related difference
in susceptibility or immune-responsiveness to Map infection
that confers long-lasting immunity in adult animals (6). We
developed the reagents and methods needed to study the ex vivo
Abbreviations: APC, antigen-presenting cells; pA, bovine growth hormone
polyadenylation signal; CBS, calf bovine serum; CTL, cytotoxic T cells;
cRPMI, complete culture medium; cDC, conventional dendritic cells;
DMSO, dimethyl sulfoxide; EMEM, Eagle’s minimal essential medium; EDTA,
ethylenediaminetetraacetic acid; FBS, fetal bovine serum; GFP, green fluorescence
protein; CMV, human cytomegalovirus; EF1α, human elongation factor 1 alpha
promoter; HEK, human embryo kidney; HKB-11, human kidney/B cell hybrid;
tPA, human tissue plasminogen activator signal peptide; Map, Mycobacterium
avium subsp. paratuberculosis; eMMP, MMP expressed in E. coli; MoDC,
monocyte-derived dendritic cells; mdPBMC, monocytes depleted PBMC;
MoM8, monocyte derived macrophages; GlcNAc, N-acetyl-D-glucosamine; NP,
nanoparticles; Ptb, paratuberculosis; PBMC, peripheral blood mononuclear cells;
PBS, phosphate buffered saline; PEI, polyethylenimine; PMA-QPCR, propidium
monoazide quantitative PCR; qRT-PCR, quantitative real-time PCR; MMP, 35
kDa membrane peptide.
immune response toMap to answer this question, and to analyze
the immune response to candidate vaccines.
Initial studies comparing the immune response to Map in
experimentally and naturally infected cattle revealed a possible
age-related difference in the development of the CD8T cell
response to mycobacterial antigens (17, 18). The proliferative
response of CD4T cells to mycobacterial antigens was early
and vigorous in experimentally infected calves, and the CD8T
cell response increased over time (18). The CD4 and CD8T
cell proliferative responses to mycobacterial antigens were
strong in naturally infected cattle. Although differences in
immune responses were detected, no age-related difference in
susceptibility to infection was found. Adaptation of methods to
use site-directed mutagenesis withMap provided an opportunity
to develop and compare the immune response to mutants with
deletions in genes associated with virulence (19). We were
particularly interested in relA, a global gene regulator. Studies
with a relA deletion mutant inMycobacterium tuberculosis (Mtb)
in a mouse model revealed that the mutant was unable to
establish a persistent infection (20).
A relA deletion mutant was developed in Map (1Map/relA),
and a similar decrease in bacterial survival was noted (21).
Analysis of the ex vivo immune response revealed the loss of
ability to establish a persistent infection was attributable to
development of CD8 cytotoxic T cells (CTL) with the ability to
kill intracellular bacteria, a function essential for development
of an attenuated mutant vaccine for Map (22). Further analysis
of the recall response to 1Map/relA using PBMC from a steer
vaccinated with the 1Map/relA mutant revealed that the target
of the response was a 35-kDa membrane-associated molecule
encoded by MAP2121c, MMP (22, 23). Comparison of the recall
response demonstrated a comparable CTL response could be
elicited with live 1Map/relA or MMP, suggesting that it might
be possible to develop an MMP peptide-based vaccine. Ex vivo
studies demonstrated that the same CD8 CTL activity could be
elicited with antigen-presenting cells (APC) pulsed with MMP
alone or incorporated into a nanoparticle-based vector (24).
The most recent studies revealed two important findings. The
first is that the nanoparticle (NP)-based approach to peptide-
based vaccination is not the best for production of a vaccine
for field use, and that other methods should be explored. The
second finding relevant to development of vaccines in general
is that development of CD8 CTL against MMP only occurred
if CD4 and CD8T cells recognized their respective antigenic
epitopes, presented by APC, at the same time (submitted for
review). The proliferative and CD8 CTL response to antigens
presented by APC pulsed with MMP was blocked in the presence
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of antibody to either MHC class I or class II molecules. This
finding revealed that any form of MMP developed for use in
a vaccine must be designed in a configuration that retains the
features of the nativemolecule associated with antigen processing
for cross-presentation of peptides in the context of MHC class I
and class II molecules.
The present study was conducted to determine if the native
gene sequence encoding MMP could be modified for expression
in mammalian cells and retain its full immunogenic properties,
a prerequisite for its potential use in a vector designed for
expression in mammalian cells.
MATERIALS AND METHODS
Mammalian Cell Lines
Human Embryo Kidney (HEK) 293T (ATCC: CRL-11268)
and Human Kidney/B Cell Hybrid (HKB-11) (ATCC: CRL-
12568) cells were maintained as suggested by the manufacturer’s
instructions. All cell lines were cultured in Eagle’s Minimal
Essential Medium (EMEM, Gibco) containing 10% fetal bovine
serum (FBS), 2mM of L-glutamine (Gibco), 100 IU/ml of
penicillin (Gibco), 100µg/ml of streptomycin (SIGMA), and
0.25µg/ml of amphotericin B (Gibco), and were incubated at
37◦C/5% CO2 in a humidified incubator.
Sequence Analysis and Cloning of MMP
The human codon-usage adapted MMP synthetic ORF was
modified from the published sequence for the hypothetical
protein MAP_2121c, Map K-10 (NCBI GenBank: AAS04438.1).
In this synthetic construct, a Kozak’s sequence, the human tissue
plasminogen activator signal peptide (tPA), and an AU1 peptide
tag were added to the human-adapted ORF sequence at the 5′
terminus and at the 3′ terminus, respectively, generating tPA-
MMP. In addition, two synthetic mutants, tPA-MMP-5mut and
tPA-MMP-2mut, were generated. In this step, all five predicted
N-glycosylation sites (tPA-MMP-5mut) or only the first two
predicted N-glycosylation sites (tPA-MMP-2mut) were mutated.
Using PCR amplification, restriction sites were added to
the 3′ and 5′ termini of tPA-MMP, tPA-MMP-5mut, and
tPA-MMP-2mut to facilitate subsequent cloning. Briefly, the
primer pair NheI-p35-sense (5′-CCCCGCTAGCCCACCATG
GACGCTATGAAGAGGGGCCTGTGCTGC-3′) and SmaI-p35-
antisense (5′-CCCCCCCGGGTTAGATGTACCGGTAGGTGT
CCTTGTACTC-3′) was used to insert a NheI restriction site
at the 5′ end and a SmaI restriction site at the 3′ end of the
ORF. The PCR amplification reaction was performed in a final
volume of 50 µl, containing 10mM Tris–hydrochloride pH
8.3, 10% dimethyl sulfoxide (DMSO), 0.2mM deoxy nucleotide
triphosphates, 2.5mM MgSO4, 50mM KCl, and 0.25µM of
each primer. tPA-MMP, tPA-MMP-5mut, and tPA-MMP-2mut
DNA were first linearized with HindIII to facilitate polymerase
action and then amplified over 35 cycles consisting of 1min of
denaturation at 94◦C, 1min of primer annealing at 60◦C, and
1min of chain elongation with 1U of Pfu DNA polymerase
(Thermo Scientific) at 72◦C. The amplicons were subsequently
checked in 1% agarose gel and visualized using ethidium bromide
staining in 1× TAE buffer (40mM Tris–acetate, 1 mM EDTA).
Later, the NheI/SmaI cut amplicons were cloned into
the shuttle vector pINT2EGFP (25) and cut with the same
enzymes, generating pCMV-tPA-MMP, pCMV-tPA-MMP-5mut,
and pCMV-tPA-MMP-2mut, thereby placing the tPA-MMP
ORFs under the transcriptional control of the immediate early
gene promoter of human cytomegalovirus (CMV), followed
by the bovine growth hormone polyadenylation signal (pA).
Alternatively, the NheI/SmaI cut amplicons were subcloned into
the vector pEF1α-p67 (26) to put the tPA-MMP ORFs under
the transcriptional control of the Human Elongation Factor 1
Alpha (EF1α) promoter followed by the bovine growth hormone
pA, thus generating pEF1α-tPA-MMP, pEF1α-tPA-MMP-5mut,
and pEF1α-tPA-MMP-2mut.
The pEF1α-tPA-MMP-CMV-EGFP:T2A:Puro lentiviral
vector was obtained by subcloning the NheI/SmaI cut, tPA-MMP
amplicon into the third-generation, replication-incompetent,
lentiviral vector pLV-EGFP:T2A:Puro (Cyagen), linearized using
NheI/EcoRV digestion, to place themodified tPA-MMP sequence
under the transcriptional control of the EF1α promoter.
PNGase F Digestion
PNGase F (New England BioLabs) was used as suggested by
the manufacturer. Briefly, serum-free medium supernatants
from pEF1α-tPA-MMP, pEF1α-tPA-MMP-5mut, and pEF1α-
tPA-MMP-2mut-transfected HEK cells, collected after 72 h
of secretion, were digested with PNGase F, which cleaves
between the innermost N-Acetyl-D-Glucosamine (GlcNAc)
and asparagine residues from N-linked glycoproteins. Twenty
micrograms of glycoproteins was denatured at 100◦C for 10min
in the presence of 10× Glycoprotein Denaturing Buffer; after
chilling on ice and a brief centrifuge of 10 s, GlycoBuffer 2
(10×), NP-40 10%, water, and 1 µl of PNGase F (500,000
U/ml) were added. The reaction was incubated for 1 h at 37◦C.
After PNGase digestion, tPA-MMP was detected using Western
immunoblotting as described below.
Transient Transfection and Secretion of
tPA-MMP From Hek 293T Cells
To evaluate the expression and secretion of tPA-MMP, HEK
293T cells were transiently transfected with pCMV-tPA-MMP,
pCMV-tPA-MMP-5mut, pCMV-tPA-MMP-2mut, pEF1α-tPA-
MMP, pEF1α-tPA-MMP-5mut, pEF1α-tPA-MMP-2mut, pEF1α-
tPA-MMP-CMV-EGFP:T2A:Puro, pEF1 α-iresGFP (pWPI, from
Addgene), or pEGFP-C1 (Clontech), using polyethylenimine
(PEI) transfection reagent (Polysciences, Inc.). Briefly, cells were
seeded at 3 × 105 cells/well in six-well plates and incubated
overnight at 37◦C/5% CO2 in a humidified incubator. Cells
were then incubated for 6 h with a transfection mix containing
3 µg of plasmid DNA and PEI (ratio 1:2.5 DNA-PEI) in
Dulbecco’s modified essential medium (DMEM) high glucose
(Euroclone) without serum. After incubation, the transfection
mix was replaced by fresh medium EMEM, with 10% FBS, 100
IU/ml of penicillin, 100µg/ml of streptomycin, and 0.25µg/ml
of amphotericin B, and incubated for 24 h at 37◦C/5% CO2 in a
humidified incubator. To test supernatant protein expression, the
transfection solution was replaced with fresh DMEM/F12 (ratio
1:1)mediumwithout FBS and incubated for 48 h at 37◦C/5%CO2
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in a humidified incubator. Cell supernatant was then collected
and analyzed by immunoblot.
Lentivirus Reconstitution and Transduction
HEK 293T cells were transfected in a T175 cm2 flask with
25 µg of pEF1α-tPA_MMP-CMV-EGFP:T2A:Puro or pEF1α-
iresGFP transfer vectors, 13 µg of p8.74 packaging vector, 10 µg
of pMD2 pseudotyping vector, and 10 µg of pREV using PEI
transfection reagent (Polysciences, Inc.). Briefly, 58 µg of DNA
was mixed with 145 µg of PEI (1 mg/ml) (ratio 1:2.5 DNA-PEI)
in 3ml of Dulbecco’s modified essential medium (DMEM) high
glucose (Euroclone) without serum. After 15min of incubation
at room temperature, 4× volumes of medium without serum
were added and the transfection solution was transferred to the
cell monolayer and left for 6 h at 37◦C/5% CO2, in a humidified
incubator. The transfection mixture was then replaced with
25ml of fresh medium EMEM supplemented with 10% FBS, 50
IU/ml of penicillin, 50µg/ml of streptomycin, and 2.5µg/ml of
amphotericin B, and cells incubated for 48 h at 37◦C/5% CO2.
The flask was then stored at−80◦C. Lentivirus was later obtained
by subjecting cells to three freeze–thaw cycles and then clarifying
the supernatant via centrifugation at 3500 rpm for 5min at
4◦C and filtering through a 0.45-µm filter (Millipore). The
clarified, lentivirus-containing supernatant was stored at−80◦C.
To obtain stably transduced cell lines, 1× 105 HKB-11 cells were
infected with 2 × 105 T.U. (transducing units) of reconstituted
tPA-MMP lentivirus. Cells were incubated overnight at 37◦C/5%
CO2. The culture medium was then replaced with fresh medium
supplemented with 10% of FBS. Transduced cells were observed
daily via fluorescence microscopy for green fluorescence protein
(GFP) expression to monitor the rate of transduction and
were selected with 1µg/ml of Puromycin to achieve a 100%
transduction rate.
Immunoblot
Protein cell extracts were obtained from pCMV-tPA-MMP,
pCMV-tPA-MMP-5mut, pCMV-tPA-MMP-2mut, pEF1α-tPA-
MMP, pEF1α-tPA-MMP-5mut, pEF1α-tPA-MMP-2mut, and
pEGFP-C1 transfected HEK 293T, or from tPA-MMP lentivirus
stably transduced HKB-11 cells and non-transduced control
HKB-11 cells by adding 100 µl of cell extraction buffer
(50mM Tris-HCl, 150mM NaCl, and 1% NP-40; pH 8).
After BCA total protein quantification (PierceTM BCA Protein
Assay kit, Thermo Scientific), cell extracts containing various
amount of total protein were electrophoresed through 10% SDS-
PAGE. Proteins were then transferred to nylon membranes by
electroblotting, and membranes were incubated with anti-AU1
rabbit polyclonal antibody (A190-125A, Bethyl Laboratories Inc.)
diluted 1:10.000, washed, and then incubated with a goat anti-
rabbit secondary antibody labeled with horseradish peroxidase
(Sigma), diluted 1:15,000 and visualized by enhanced chemi-
luminescence (Clarity Max western ECL substrate, Biorad). Also,
cell supernatants, obtained fromHEK 293T cells transfected with
pCMV-tPA-MMP, pCMV-tPA-MMP-5mut, pCMV-tPA-MMP-
2mut, pEF1α-tPA-MMP, pEF1α-tPA-MMP-5mut, pEF1α-tPA-
MMP-2mut, and pEGFP-C1 and from all the transduced cell
lines, were collected after 72 h in serum-free medium DMEM-
F12 secretion condition and analyzed through 10% SDS–PAGE
gel electrophoresis.
Blood Source
Blood required to conduct the study of the immune response
to mammalian-expressed MMP peptides was obtained from
three Map-free Holstein steers housed in an open feed lot
and maintained by the WSU animal care staff. All protocols
were approved by the Washington State University Institutional
Animal Care and Use Committee (ASAFs 3360 and 04883).
Cell Separation and Culture
Peripheral blood mononuclear cells (PBMC) were prepared
by density gradient centrifugation. One portion of the PBMC
was used to generate monocyte-derived macrophages (MoM8)
for use in a propidium monoazide quantitative PCR (PMA-
QPCR) viability assay (22). This portion of the PBMC was
re-suspended in complete RPMI culture medium (cRPMI)
[RPMI-1640 medium with GlutaMAXTM (Life Technologies,
CA) supplemented with 10% calf bovine serum (CBS), 1mM β-
mercaptoethanol, 100 units/ml of penicillin G, and 100µg/ml
of streptomycin sulfate] and cultured overnight in 150-mm
tissue culture plates. The following day, non-adherent cells were
removed and adherent cells were cultured in fresh medium
for 6 days. On day six, the adherent cells were brought
into suspension by incubation on ice in the presence of
ethylenediaminetetraacetic acid (EDTA) in phosphate buffered
saline (PBS) [4ml EDTA (250mM stock in H2O), 5ml CBS,
and 91ml PBS]. Then, the MoM8 were distributed into six-well
culture plates (2 × 106 cells/well) and cultured for an additional
6 days in fresh cRPMI at 37◦C/5% CO2.
The second PBMC portion was subjected to magnetic
separation using microbeads coated with a cross-reactive anti-
human CD14 mAb to isolate monocytes per the manufacturer’s
instructions (Miltenyi Biotec) (27). Isolated monocytes (2× 106)
were added to wells of six-well culture plates and cultured in 3ml
of cRPMI in the presence of a DC growth cocktail containing
bovine GM-CSF and IL-4 according to the manufacturer
instructions (Kingfisher Biotech,MN). On the third day, 1.4ml of
themediumwas replaced with 1.8ml of freshmedium containing
the cocktail. The cultures were incubated for an additional 3 days
to obtain monocyte-derived dendritic cells (MoDC).
Flow-through containing monocyte-depleted PBMC
(mdPBMC) were subjected to two rounds of antigenic
stimulation using APC (cDC present in mdPBMC) (22, 28)
pulsed with MMP expressed in E. coli (eMMP) (29) or tPA-MMP,
tPA-MMP-5mut, or tPA-MMP-2mut. To conduct the first round
of stimulation, mdPBMC were distributed in the six-well culture
plate in duplicate (2 × 106/ml in 5ml of cRPMI). Peptides were
added to the indicated wells in a concentration of 5µg/ml, and
the cultures incubated for 6 days at 37◦C, 5% CO2 to allow
antigen processing and presentation by conventional dendritic
cells (cDC) present in the mdPBMC. To conduct the second
round of stimulation after 6 days of culture, peptides were
added to the cultures of MoDC at the same concentration and
incubated for 3 h at 37◦C, 5% CO2. Then, peptide-pulsed MoDC
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TABLE 1 | mAbs used in the present study.
mAb clone Isotype Specificity/source Fluorochrome
CAM36A IgG1 CD14 WSUMAC Alexa Fluor®647
209MD26A IgG2a CD209 WSUMAC PE CY5.5
ILA11A IgG2a CD4 WSUMAC PE CY5.5
CACT138A IgG1 CD4 WSUMAC Alexa Fluor®647
7C2B IgG2a CD8 WSUMAC PE CY5.5
CACT80C IgG1 CD8 WSUMAC Alexa Fluor®647
ILA116A IgG3 CD45R0 WSUMAC Alexa Fluor®488; PE CY7
CACT116A IgG1 CD25 WSUMAC Alexa Fluor®647
Data were collected on a modified FACS Calibur DxP8 Analyzer equipped with a FlowJo
operating system (Cytek Biosciences Inc., Fremont, CA) and analyzed with FCS Express
software (DeNovo Software, Glendale, CA) (30). For data acquisition, side scatter (SSC)
and forward scatter (FSC) were used to identify small and large lymphocytes. FSC-
Height vs. FSC-Width (FSC-H vs. FSC-W) was used to exclude doublets. Additional
gates were used to select CD4 and CD8T cells for determination of their activation status
and proliferation.
were washed three times with warm RPMI to remove cell-free
antigens. The non-adherent primed PBMC were collected,
washed with warm RPMI, and then added to their respective,
autologous, antigen-pulsed MoDC (2 × 106/ml in 5ml of
cRPMI). After an additional 6 days of culture, the cells were
collected and used in FC and theMap PMA-QPCR viability assay
as described below. One set of mdPBMC were maintained as
negative controls with no antigen stimulation during the 2 weeks
of cell culture.
Flow Cytometry
Cell activation and proliferation were assessed using FC as
previously described (22). Briefly, cells were washed once in
PBS/ACD, re-suspended in serum-free RPMI, and counted.
Cells were distributed into 96-well polystyrene V-bottom
microplates (106 cells/well) and labeled with combinations of
mAbs obtained from the WSU Monoclonal Antibody Center
(WSUMAC) (Table 1).
PMA-QPCR Viability Assay
To determine the cytotoxic activity of effector T cells generated
after two rounds of stimulation with the different peptides, the
liveMap burden in infected MoM8 co-cultured with the effector
T cells was assessed using the PMA-QPCR viability assay. In this
case, one aliquot of Map K10 stock (ATCC BAA-968/K10) was
inoculated in Middlebrook 7H9 broth (Difco, BD Biosciences,
USA) supplemented with 6.7% para-JEM GS (Trek Diagnostic
Systems, OH), 2µg/mlmycobactin J (AlliedMonitor, MO, USA),
and 0.05%Tween 80 (Sigma-Aldrich Corp.) (19, 21). The cultures
were expanded on a shaking stand at 37◦C until they reached an
OD600. Master stock for immediate use in each experiment was
prepared in 1.5ml micro-centrifuge screw-cap tubes. Bacterial
suspension was disaggregated by passages through a 26-gauge
needle three times, and bacterial numbers were estimated based
on the final OD600 values (19) and used for MoM8 infection.
MoM8 were infected with Map K10 at a multiplicity of
infection (MOI) of 10:1 (2× 107 Map to∼2× 106 MoM8/well)
in antibiotic-free cRPMI for 3 h as previously described (22).
Antigen stimulated and control unstimulated mdPBMC were
collected and co-cultured with the infected MoM8 for 24 h at
37
◦
C, 5% CO2. All non-adherent and adherent cells per well were
collected and lysed for 15min using 0.01% saponin in H2O at
37◦C. A set of controls (100% live, 50% live/50% killed, and 100%
killed) was prepared from known mixtures of live and deadMap
K10 to cover the dynamic range of Cycle threshold (CT) values
for live vs. dead Map obtained from infected MoM8 before and
after incubation with the effector cells. Each aliquot contained 2
× 107 total Map. Aliquots were used to infect MoM8 cultures
as described followed by co-culture with 107 fresh mdPBMC per
well. Then, all cells in each well were immediately lysed with
saponin as described above. All lysates were then treated with
propidium monoazide (PMA) in a final dye concentration of
50µM as previously described (22) followed by light exposure
for 5min using a halogen lamp with a 650W bulb. Cells were
subsequently processed for DNA isolation according to the
protocol for Gram-positive bacteria using DNeasy R© Blood and
Tissue kit (Qiagen, USA) as described by Park et al. (31).
The single-copy F57 gene specific for Map was used in
the TaqMan Quantitative Real-Time PCR (F57 qRT-PCR) to
determine the viability of intracellularMap as described by Kralik
et al. (32) and Abdellrazeq et al. (22). Pure Map gDNA was
used to generate a standard curve using eight dilutions starting
with 4 × 107 copies. The reaction was performed according
to Schönenbrücher et al. (33) using a StepOnePlus Real-Time
PCR machine (Applied Biosystems, CA). The mean values of
the CT were analyzed using StepOne Software v2.1 (Applied
Biosystems, CA).
Statistics
Data were imported into SAS software (SAS for Windows
version 9.3 and JMP version 12.0.1; SAS Institute Inc., Cary,
NC) for statistical analysis and graphical presentation (means
and standard deviations). Two-way ANOVA was used to
conduct statistical analyses. Post-hoc multiple comparisons were
conducted using Tukey HSD (overall α= 0.05). ∗P < 0.05; ∗∗P <
0.01; ∗∗∗P < 0.001.
RESULTS
Topological Prediction
Initial data obtained with MMP demonstrated that it is a
good candidate antigen for use in a peptide-based vaccine (22).
MMP incorporated into an NP vector retained its CTL activity
(24). However, methods for incorporating the peptide into the
NP vector proved unreliable with some preparations having
no activity. Therefore, we explored the potential of modifying
the gene encoding MMP for expression in a mammalian
expression vector for use in cattle and other species. It was
unclear whether modifications in the amino acid sequence
needed for expression in mammalian cells would alter the
immunogenicity of MMP. Initial studies suggested that MMP
is membrane associated (29). Further studies revealed that the
peptide is associated with a cysteine desulferase (MAP2120c)
in the membrane (23). In the present study, in silico analysis
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using the Phobius (http://phobius.sbc.su.se/) prediction server
for presence of transmembrane domains and signal peptides
did not detect a canonical signal peptide or hydrophobic region
(Supplementary Figure 1). Indeed, an MMP-like sequence in
mammalian cells appeared to be intracellularly localized and
very soluble.
Codon Usage Adaptation and Synthetic
Gene Design
SinceMMP is a bacterial protein, codon usage had to be modified
before attempting to develop an expression cassette for use in
mammalian cells. This was accomplished with use of the Jcat
codon adaptation tool to change the MMP ORF nucleotide
codon composition to a composition based on human genome
codon usage (http://www.jcat.de/) (Supplementary Figure 2). A
Kozak’s sequence and a human tissue plasminogen activator
(tPA) signal peptide were added to the modified MMP to
generate tPA-MMP, followed by addition of two restriction
enzyme sites to both ends to improve the translation, secretion,
and subcloning into a suitable vector. The modified tPA-MMP
was sent out for synthesis. Reanalysis of the modified sequence
using Phobius revealed that the addition of the signal peptide
to generate the tPA-MMP ORF customized for human codon
usage shifted its predicted sub-cellular localization to a secreted
protein (Figure 1).
Construction and Transient Expression of
tPA-MMP in a Secreted Form
As described, the tPA-MMP was provided with a heterologous
signal peptide to facilitate expression and secretion by
mammalian cells. The synthetic tPA-MMP (Figure 1A) was
placed under the transcriptional control of the Elongation
Factor 1 alpha (EF1α) promoter, followed by the bovine growth
hormone polyadenylation signal to obtain an EF1α-tPA-MMP
expression cassette. The expression cassette was integrated into
a mammalian expression vector (pEF1α-tPA-MMP) and into
a lentiviral vector (pEF1α-tPA-MMP-CMV-EGFP:T2A:Puro)
(Figure 2A). pEF1α-tPA-MMP transiently transfected HEK293
cells and pEF1α-tPA-MMP-CMV-EGFP:T2A:Puro transduced
HEK 293T cells secreted the tPA-MMP peptide (Figures 2B,C).
tPA-MMP Peptide Expressed by
Mammalian Cells Is Glycosylated
tPA-MMP products extracted and secreted from mammalian
cells migrated with a lower mobility than expected (Figure 2B),
indicating a molecular weight higher than 35 kDa (∼43 kDa),
which is in contrast with what was previously published (34).
In fact, MMP was originally called the “M. paratuberculosis 35
kDa major membrane protein” (34). Based on this observation,
a possible glycosylation of MMP expressed in mammalian
cells was considered. Moreover, tPA-MMP detected in the
cell extract had two bands: One could be the glycosylated
fraction, and the second, the un-glycosylated fraction of the
protein (Figure 2B). The tPA-MMP detected in the secreted
peptide fraction showed just a single band of ∼43 kDa,
attributable to a glycosylated protein form of MMP, in agreement
with the fact that secreted proteins in mammalian cells are
post-translationally modified, in this case, glycosylated. To
explore this possibility, the MMP peptide-modified sequence
was analyzed with different glycosylation site prediction
programs (Glyco EP, http://www.imtech.res.in/cgibin/glycoep/
glyechk?job=932&tim=45; NetGlyc 1.0, http://www.cbs.dtu.dk/
services/NetNGlyc/; Protter, http://wlab.ethz.ch/protter/#). All
three of the analysis programs yielded highly concordant
results. Three potential N-linked and two O-linked glycosylation
sites were predicted (Figure 3A). Among all these predicted
sites, the first two N-linked glycosylation sites showed the
higher scores in terms of prediction. This prediction was
validated by treating the secreted tPA-MMP with PNGase F,
an amidase that cleaves between the innermost GlcNAc and
asparagine residues of high mannose. As shown in Figure 3B,
PNGase F treatment of tPA-MMP shifted its molecular size
down to ∼35 kDa. These data were further corroborated
by mutating the five potentially glycosylated residues of tPA-
MMP (tPA-MMP-5mut), where the three asparagines and
the two threonines were substituted with glutamine in order
to eliminate all potential glycosylation sites (Figure 4A).
Secreted tPA-MMP-5mut showed the same mobility of secreted,
PNGase F-treated tPA-MMP (Figure 4B). Therefore, it was
hypothesized that there is no O-linked glycosylation and
that tPA-MMP N-linked glycosylation is only related to the
first two asparagine residues, affirming the higher prediction
scores of the first two predicted N-linked glycosylation sites
in respect to the third predicted site. This hypothesis was
further validated by generating a second tPA-MMP mutant, tPA-
MMP-2mut, in which only the first two asparagine residues
were substituted with glutamine (Supplementary Figure 3). In
fact, secreted tPA-MMP-2mut, tPA-MMP-5mut, and PNGase F-
treated tPA-MMP showed identical patterns of electrophoretic
mobility (Figure 4C).
Expression Levels of tPA-MMP-2mut and
tPA-MMP-5mut Are Lower Than that of
tPA-MMP
Although tPA-MMP-2mut, tPA-MMP-5mut, and tPA-MMP
were expressed, quantitative differences were observed in the
amount of secreted product. Therefore, all three constructs
were cloned under the control of two different promoters,
EF1α and CMV, to exclude a different promoter contribution
in terms of transcription. Intracellular protein production
was analyzed to assess the impact of protein glycosylation
on protein secretion. As shown in Figure 5, less of the
tPA-MMP-5mut of the intracellularly expressed and secreted
products were expressed in comparison with tPA-MMP-
2mut and tPA-MMP expressed and secreted products. Since
the tPA-MMP-5mut is un-glycosylated like tPA-MMP-2mut,
and the tPA-MMP has similar intracellular expression and
secretion levels compared to tPA-MMP-2mut, the quantitative
expression difference could be attributed to tPA-MMP-5mut
ORF mutations that might affect tPA-MMP-5mut transcription
stability. Studies were conducted to explore this possibility.
Similar data were obtained using the two different transcription
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FIGURE 1 | (A) MMP nucleotide sequence with human tPA signal peptide (green), along with the deduced amino acid sequence (tPA-MMP). The AU1 tag is
highlighted in yellow. (B) Server output prediction of transmembrane topology and signal peptides from the amino acid sequence of MMP protein compared with (C)
MMP amino acid sequence with the human tPA signal peptide (tPA-MMP). In tPA-MMP (C), but not MMP (B), a signal peptide is detected and the protein is predicted
to be secreted, reaching the top score of probability (1).
promoters on the three different tPA-MMP ORFs (Figure 5),
thus excluding transcriptional differences as an explanation
for the observed differences in the level of expression of
products. Expression appeared to be slightly more efficient
under the control of the CMV promoter in the transient
transfection assay.
Comparison of the CD4 and CD8T Cell
Proliferative Response to APC Pulsed With
eMMP, tPA-MMP, tPA-MMP-2mut,
tPA-MMP-5mut Peptides-Stimulated Cells
Development of an MMP expression cassette for insertion
into a mammalian expression vectors was successful. The next
series of studies were conducted to establish that the modified
expressed products retained the immunogenic and functional
activities of the native peptide expressed in E. coli, eMMP.
The ex vivo platform developed to study the immune response
to candidate vaccine antigens was used in conjunction with a
bacterium viability assay to compare the immune response of
the modified tPA-MMP products with the immune response
elicited with eMMP (22). The initial studies conducted during
the development of the assays revealed that the flow cytometric
assay could be used to phenotype the lymphocytes proliferating
in response to stimulation with APC [conventional dendritic cells
(DC) present in PBMC depleted of monocytes and monocyte
derived DC] pulsed with live bacteria or peptides. For study
of the recall and CTL response, one round of stimulation
with antigen was sufficient to elicit a proliferative response
for phenotyping following 6 days of culture and for analysis
of their functional activity using the bacterium viability assay.
Two rounds of stimulation with APC pulsed with antigen
were needed to expand the culture of proliferating antigen
specific T cells for flow cytometry and for analysis of their
functional activity using the bacterium viability assay. This
time interval provided sufficient time to generate autologous
monocyte-derived macrophages for use as infected target cells.
As outlined in section Materials and Methods, half the respective
preparations of control and stimulated cells were used for
phenotyping, and the other half were used in the killing assay.
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FIGURE 2 | (A) Diagram of a third-generation lentiviral transfer vector delivering tPA-MMP ORF (tPAp35AU1, green) expression cassette and GFP/Puromycin reporter
gene/selectable marker (EGFP:T2A:Puro, purple) expression cassette. Different genetic elements depicted within the construct from nucleotide position 0 are: RSV
promoter (blue violet); 15′ LTR (brown); 9 (medium blue); RRE (chocolate); cPPT (brown); EF1α (navy); WPRE (royal blue); CMV promoter (orchid); 1U3/3’ LTR
(sienna); Sv40 early pA (red); Ampicillin (turquoise); pUC ori (dark salmon). (B) Western immunoblot of pEF1α-tPA-MMP and pEGFP-C1 transfected HEK 293T cell
extracts and supernatant. Lanes with cell extract were loaded with 20 µg of total protein, whereas the lanes with supernatant were loaded with 20 µl of serum-free
medium incubated for 48 h with transfected cells. Cells transfected with pEGFPC-1 served as negative controls (Mock). (C) Western immunoblot of
pEF1a-tPA-MMP-CMV-EGFP:T2A:Puro-transduced and Puromicin-selected HKB-11 cells, supernatant collected at 4, 8, 24, and 48 h incubation. In each lane, 15 µl
of conditioned serum-free medium was loaded. The negative control (–) was established with a similar lentiviral vector delivering only GFP (pEF1α-iresGFP).
The latter cell preparations were added to the cultures of
autologous infected macrophages for 24 h. Then, all the cells in
the respective cultures were collected and lysed to isolate bacterial
DNA for viability analysis.
Flow Cytometric Analysis of the
Proliferative Response
The flow cytometric assay used in this study was developed
and validated in previous studies. It was designed to more
accurately identify and phenotype antigen specific CD4 and
CD8T cells proliferating in response to Ag stimulation (22, 30).
To develop the assay, a fluorescent vital dye (hydroethidine)
was used to identify all cells present in a culture of PBMC
stimulated with concanavalin A. Based on side vs. forward
light scatter (SSC vs. FSC), activated proliferating cells could
be distinguished from unactivated (resting) cells based on an
increase in size of activated/stimulated cells. The populations
could be distinguished from each other for further analysis
by placing electronic gates on the populations and adding
an artificial color to them to distinguish the two populations
(e.g., coloring unstimulated cells orange and stimulated cells
blue). When hydroethidine labeled cells were mixed with
a preparation of unstimulated PBMC, the two populations
could be distinguished from each other based on fluorescence
(hydroethidine labeled cells fluoresce in the red Fl-2 channel).
Unstimulated cells in both populations exhibited the same
pattern of color coding, distinguishing them from stimulated
cells coded with a different color. When the mixed populations
were labeled with a monoclonal antibody (mAb) specific for
CD45R0, a memory T cell marker, expressed on stimulated
and unstimulated cells, unstimulated CD45R0 positive cells in
both populations could be distinguished from the stimulated
population based on difference in color using FL2 vs. FL1.
When the mixed populations of cells were labeled with a mAb
Frontiers in Immunology | www.frontiersin.org 8 December 2019 | Volume 10 | Article 2859
Franceschi et al. Mammalia Cells Expressing Map MMP
FIGURE 3 | (A) MMP N-linked (1N, 2N, and 3N in red) and O-linked (1T and 2T in blue) predicted glycosylation sites. (B) Western immunoblot of tPA-MMP secreted
protein treated (Sup PNGase treated) or untreated (Sup untreated) with PGNase F. Cell extracts from pEF1α-tPA-MMP (Cell extract) and pEGFP-C1 (Cell extract GFP)
transfected HEK 293T cells were used as positive and negative controls, respectively.
only expressed on stimulated cells (e.g., ACT1), unstimulated
cells that did not express ACT1 could be distinguished from
stimulated cells that expressed ACT1 (30). Further studies
demonstrated that Ag specific memory CD4 and CD8T cells
proliferating in response to Ag stimulation ex vivo, could be
distinguished from unstimulated memory T cells based on
the use of selective gating alone to distinguish activated cells
based on size and expression of CD45R0 and molecules only
expressed on activated T cells. As reported here, a single
selective gate was placed on cells displayed in SSC vs. FSC
to isolate the population for analysis. A second selective
gate was placed on either CD4 or CD8T cell populations
displayed in FSC vs. CD4 or CD8. Both isolated populations
were then displayed in FSC vs. CD45R0 for analysis. A box
gate was placed on the proportion memory cells showing an
increase in size based on FSC (Supplementary Figure 4) (22).
This corresponded to the activated cells identified using the
initial color coding and gating strategy (30). The proportion
of cells present in this gate in preparation of cells from
unstimulated cultures were compared with the proportion of
cells present in stimulated cultures to determine the increase
in the proportion of cells associated with Ag stimulation.
Previous studies had documented that these cells were the
only cells positive for molecules only expressed on activated
cells. Analysis of mdPBMC pulsed with the positive control
eMMP showed that the activation and proliferative responses
of the memory CD4 and CD8T cells were consistent with
responses obtained in previous experiments using two rounds of
stimulation of mdPBMC with antigen-pulsed APC. Comparison
of the proliferative responses of CD4 and CD8T cells elicited
by eMMP with responses elicited by tPA-MMP and tPA-MMP-
2mut showed that the responses were similar. In contrast, the
proliferative response elicited by tPA-MMP-5mut was limited as
illustrated with a representative set of flow cytometric profiles
obtained from one of three duplicate sets of experiments
conducted with one of the three steers used in the study
(Figure 6). Therefore, tPA-MMP-5mut was excluded from
further analysis.
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FIGURE 4 | (A) Mutated MMP protein sequence (tPA-MMP-5mut), where the predicted N-linked asparagine residues were substituted with glutamine (Q, red) and the
predicted O-linked threonine residues were also substituted with glutamine (Q, blue). (B) Western immunoblot of secreted tPA-MMP-5mut (Sup tPA-MMP-5mut)
compared with tPA-MMP treated or untreated with PNGase. tPA-MMP-5mut and tPA-MMP treated with PNGase exhibit the same electrophoretic mobility. (C)
Western immunoblot of secreted tPA-MMP-5mut (Sup tPA-MMP-5mut) compared with tPA-MMP-2mut (Sup tPA-MMP-5mut) and tPA-MMP treated or untreated with
PNGase. tPA-MMP-5mut, tPA-MMP-2mut, and tPA-MMP treated with PNGase exhibit the same electrophoretic mobility.
Comparison of CTL Activity
As illustrated in Figure 7A, a standard curve was generated with
DNA from the single-copy gene, F57, for comparison of the
proportion of viable bacteria present in each preparation ofMap
isolated from each cell preparation. Because blocking of F57DNA
by PMA is incomplete, a second control preparation was made
from macrophages infected with a known concentration of live
and dead bacteria to establish where the concentrations of live
and dead bacteria will fall on the standard curve. This control
was also used to show the sensitivity of the assay to determine
the relative proportion of live bacteria present in each culture of
infected target cells at the time of DNA isolation. Comparison
of live bacteria isolated from control-infected macrophages
immediately after infection with live bacteria isolated at 24 h
after infection (identical to the time infected macrophages were
incubated with unstimulated and antigen stimulated mdPBMC)
showed that there was limited loss of live bacteria during the
24-h incubation period. There was also limited loss of live
bacteria in infected macrophage preparations incubated with
unstimulated mdPBMC. In contrast, there was a clear loss of live
bacteria in preparations of infected macrophages incubated with
eMMP, tPA-MMP, and tPA-MMP-2mut. Comparison of the CTL
activity of CD8T cells from the three steers that proliferated in
response to stimulation with eMMP, tPA-MMP, and tPA-MMP-
2mut showed that the CTL activity of CD8T cells stimulated with
tPA-MMP-2mut was consistently better than the CTL activity
of CD8T cells stimulated with tPA-MMP (Figure 7B). However,
both CTL responses were slightly less than the response elicited
with eMMP.
DISCUSSION
Efforts to develop vaccines against mycobacterial pathogens have
been impeded by the lack of understanding the mechanisms
used by the pathogens to establish a persistent infection. This
occurs concurrently with the development of humoral and cell-
mediated responses to the mycobacteria that are able to delay
development of clinical disease. In humans, the immune response
that develops against Mtb is sufficient to maintain immune
control for a lifetime in most exposed subjects. Clinical disease
occurs in ∼10% of individuals persistently infected with Mtb,
and is associated with impairment of immune function (35).
This may also occur in response to infection with Map in
humans (3–5, 36). Studies in cattle have shown that exposure
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FIGURE 5 | Quantitative Western immunoblot of serum-free medium containing secreted tPA-MMP-5mut, tPA-MMP-2mut, and tPA-MMP from
pCMV-tPA-MMP-5mut, pEF1α-tPA-MMP-5mut, pCMV-tPA-MMP-2mut, pEF1α-tPA-MMP-2mut, pCMV-tPA-MMP, and pEF1α-tPA-MMP transfected HEK 293T cells
at 48 h post transfection. Each lane was loaded with 15 µl of serum-free medium supernatant. The same number of HEK 293T cells were transfected with the same
amount of each DNA plasmid with the same efficiency of transfection (100%), as determined by co-transfection with pEGFP-C1. Band intensity was quantified using
densitometry (ChemiDoc; MPIMAGING SYSTEM, LAB SOFTWARE, BioRad), and displayed using a bar graph. Data were normalized as folds of increased secretion,
where pEF1α-tPA-MMP-5mut signal was considered equal to 1. The experiment was repeated three times, and statistical significance (P < 0.001) was assessed
using a Student’s t-test and one-way ANOVA.
FIGURE 6 | Representative FC profiles comparing CD4 and CD8T cell proliferation in response to peptides. FC dot-plots represent the frequency of activated
memory CD4 (first row) and CD8 (second row) T cells in unstimulated or eMMP, tPA-MMP, tPA-MMP-2mut, and tPA-MMP-5mut-stimulated mdPBMC. The profiles are
representative of replicates of the FC data obtained from the three steers used in the study.
leads to development of a latency that varies in duration, with
a breakdown in protective immunity occurring two or more
years post exposure. The immune response during the early
stages of infection is resilient and not readily disrupted by use of
immunosuppressive agents like dexamethasone or depletion of
CD4T cells at the time exposure (37). The response is sufficient
to suppress bacterial replication to the extent that it is difficult
to detect the presence of bacteria in any tissue (17). Eventually,
however, for yet to be explained reasons, protective immunity is
disrupted and clinical disease develops.
Of importance to the development of a vaccine against Map
and other mycobacterial pathogens, this evasion tactic is lost
when relA is disrupted. This was first demonstrated by Dahl
et al. using a mouse model with a relA Mtb deletion mutant.
The mutant was unable to establish a persistent infection (20).
Studies with Map revealed that deletion of relA had the same
effect. Infection with the mutant was cleared (38). Development
of a flow cytometric assay and a bacterium viability assay to
replace the cfu assay facilitated characterization of the phenotype
and functional activity of CD4 and CD8T cells proliferating
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FIGURE 7 | Intracellular Map PMA-QPCR viability assay. (A) Graphical representation of real-time PCR data for Map intracellular killing to determine the CT values
measured for amplification of the Map F57 target gene. CT values represent average of duplicate preparations of DNA isolated from pure Map (8 red oval points), Map
viability control (blue circle), Map-infected MoM8 lysed after 3 h of infection (gray pentagon), Map-infected MoM8 lysed after 24 h of infection (light gray pentagon),
cell mixture lysed after 24 h of co-culturing of Map-infected MoM8 with unstimulated mdPBMC (dark gray hexagon), cell mixture lysed after 24-h co-culture of
Map-infected MoM8 with mdPBMC stimulated twice with tPA-MMP (dark red rectangle), tPA-MMP-5mut (gold triangle), or eMMP (pink diamond). (B) Summary of
three biological replicate experiments performed in duplicate from each of the three steers comparing the killing activity following stimulation with the different MMP
peptides relative to controls. *P < 0.05; ***P < 0.001.
during the recall response following stimulation with the Map
relA mutant. Analysis revealed that clearance was attributable
to development of CD8 CTL with the ability to kill intracellular
bacteria (22). Analysis of the response led to the discovery that a
35-kDa membrane-associated peptide, MMP, is the target of the
CTL response (22). Vaccination with a replicate of the peptide
expressed in E. coli, eMMP, elicited a CTL response equivalent
to the response elicited by the 1Map/relA mutant, suggesting
that it might be possible to develop a peptide-based vaccine for
Ptb. Analysis of the immune response to the peptide revealed
a previously unrecognized feature of the response essential for
eliciting CTL. Development of CD8 CTL only occurred if CD4
and CD8T cells recognize their respective epitopes presented
by APC at the same time. Using the ex vivo test platform,
examination of the CTL response to stimulation with APC pulsed
with MMP revealed that the CTL response was blocked in the
presence of antibody to either MHC I or MHC II molecules (in
review). These results showed that development of a peptide-
based vaccine with eMMP would require retention of epitopes in
the peptide that would be processed and presented in the context
of MHC I and II molecules. This is a new salient observation that
may be relevant for development of peptide-based vaccines not
only forMap but also for other pathogens.
The first choice for a vector-based vaccine was the use
of nanoparticles. Trial experiments with a well-characterized
nanoparticle revealed that an equivalent CTL response to MMP
could be elicited ex vivo with MMP alone or incorporated in a
nanoparticle vector (24). Unfortunately, attempts to standardize
a method of production of a nanoparticle vectored MMP
vaccine for field use demonstrated that it was not possible
to make a product with reliable activity, indicating that other
approaches needed to be explored for the development of an
MMP-based vaccine.
Extensive studies have been conducted to develop and
test viral vectors for delivery of vaccines [reviewed in (39,
40)]. There has been one attempt to develop a virus-
vectored vaccine for Map (14). Methods were unavailable to
analyze the functional activity of the expressed products. To
explore the potential of developing a virus-vectored vaccine
for MMP, information from ongoing studies revealed that
the first step would require development of an expression
cassette for insertion and testing of available viral vectors
for delivery of MMP as a vaccine. Of critical importance,
studies demonstrated any modifications of the native sequence
of the gene encoding MMP must not alter the immunogenic
properties of the expressed peptide. Antigen processing of
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any modified expressed copy of MMP by APC must lead to
expression of the same epitopes in the context of MHC I
and II molecules (in review). Although extensive information
is available on the use of bacteria to express mammalian
proteins in bacteria, information is still limited on expression
of mammalian proteins through bacterial secretory pathways.
The main obstacle for both viral and DNA vector-based
vaccines delivering bacterial antigens is maintenance of antigen
authenticity when expressed by mammalian cells. In contrast to
mammalian cells, proteins expressed by bacteria do not undergo
post-translational modification. Consequentially, modification
for expression in mammalian cells could negatively impact
peptide immunogenicity. Therefore, the design of a cassette
for use in expression of bacterial proteins in mammalian
expression vectors needs to be taken into consideration. As
reported here, the first step in accomplishing this objective
was conducted on the premise that modification of the native
gene sequence encoding MMP for expression in mammalian
cells, specifically human derived cell lines, would yield an
expressed product with the same immunogenic activity as
the native molecule expressed by MAP2121c. Proof of this
premise would not be known until a modified sequence was
developed and used to express a product for analysis of its
immunogenic properties.
In silico analysis of the MMP sequence was conducted to
predict the protein topology when expressed in mammalian
cells. Although previous studies provided data indicating MMP
is localized on the surface in complex with another peptide
(23, 29), it was surprising to find that the peptide did not
contain a canonical signal peptide, transmembrane domain,
or a GPI anchor to sort and link MMP to the bacterial cell
surface. In fact, the in silico analysis predicted localization
of MMP in the cytoplasm of transfected or transduced
mammalian cells. However, the finding is not unprecedented.
Similar observations have been obtained in the study of other
mycobacteria (41, 42).
Protein expression levels are closely related to genetic
sequences, which are often similar but never identical between
species of organisms. Comparative studies have revealed the
use of two to six different synonymous DNA triplets to encode
the same amino acid with some of the codons used more
frequently than others, a phenomenon defined as codon usage
bias, which is directly related to gene expression efficiency.
This must be considered when modifying codon usage for
expression of recombinant proteins by different species, in order
to obviate codon usage differences and maximize efficiency
of expression (43–45). In this study, MMP ORF codon usage
was modified with the aid of the Java Codon Adaptation
Tool (JCat) for expression of MMP in mammalian cells.
The adapted MMP ORF sequence was modified further to
include a mammalian signal peptide sequence to facilitate
efficient intracellular expression and extracellular secretion.
A third-generation, replication-incompetent pEF1α-tPA-MMP-
CMV-EGFP:T2A:Puro lentiviral vector was used to generate
a recombinant lentivirus tPA-MMP expression cassette. Initial
use of the cassette demonstrated that it could be used to
successfully transduce different cell lines and primary cell
cultures (data not shown). Particularly, we generated stableMMP
lentivirus transduced human cell lines constitutively secreting
tPA-MMP, tPA-MMP-2mut, and tPA-MMP-5mut for ex vivo
immunization studies. We took advantage of the ability to
culture the transduced cell lines in serum-free medium to
produce supernatants containing the three variants of tPA-MMP
almost free of non-specific proteins for use in analysis of its
immunogenic activity.
SDS-PAGE and Western blot analysis of the secreted
products revealed that they exhibited a slightly higher molecular
weight than the expected ∼35 kDa of the native MMP.
In silico examination of the modified amino acid sequence
of tPA-MMP using different software programs revealed that
some amino acids that might be glycosylated, explaining
the unexpected difference in the pattern of electrophoretic
migration. To explore this possibility, asparagine residues in
tPA-MMP predicted to be potential sites for N-glycosylation
were substituted with glutamine, a structurally similar amino
acid that is not a target for glycosylation or fucosilation.
In addition, supernatants containing the tPA-MMP variants
were digested with PNGase F, a deglycosylation enzyme. Both
manipulations of the modified tPA-MMP confirmed that N-
linked glycosylation occurred when the expression vector
was transfected or transduced into mammalian cells. Both
manipulations yielded a product with the expected molecular
weight of native MMP as detected by its pattern of migration
in SDS-PAGE.
Following physical characterization of the modified forms
of tPA-MMP, it was possible to finally determine if the
modifications of MMP for expression in a mammalian cell
altered the capacity of MMP to elicit CTL activity essential
for use of MMP in a peptide-based vaccine. As reported,
the use of the ex vivo platform and bacterium viability assay
facilitated analysis of the proliferative and functional activity
of tPA-MMP and the mutants in comparison with MMP
expressed in E. coli (eMMP). Comparison of the proliferative
responses revealed that stimulation with APC pulsed with
eMMP, tPA-MMP, and the tPA-MMP-2mut yielded similar
proliferative responses. Stimulation with tPA-MMP-5mut yielded
minimal proliferation, suggesting that the exchange of asparagine
with glutamine affected the immunogenic characteristics of
the peptide. Based on this finding, tPA-MMP-5mut was
excluded from further testing. Additional comparisons of
the capacity of the expressed, modified tPA-MMPs revealed
modest difference in the capacity of tPA-MMP and tPA-
MMP-2mut to elicit CTL response. The findings suggest that
both tPA-MMP and tPA-MMP-2mut are suitable candidates
for use in a virus-vectored vaccine for Map. Further studies
are now warranted to use the shuttle vector to develop
virus vectors containing tPA-MMP or tPA-MMP-2mut to test
for efficacy.
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